TY - JOUR
T1 - Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production
AU - Yamada, Hisakata
AU - Tsuru, Tomomi
AU - Otsuka, Takeshi
AU - Maekawa, Masayuki
AU - Harada, Hiroshi
AU - Fukuda, Takaaki
AU - Tsukamoto, Hiroshi
AU - Maeyama, Akira
AU - Yoshizawa, Shigeru
AU - Wada, Ken
AU - Nakashima, Yasuharu
AU - Shono, Eisuke
AU - Yoshizawa, Seiji
AU - Jojima, Hiroshi
AU - Kondo, Masakazu
N1 - Funding Information:
The authors thank Clinical Research Support Center Kyushu (CReS, Fukuoka, Japan) for handling and analyzing the data.
Publisher Copyright:
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of the Japanese Society of Clinical Immunology.
PY - 2020/4/2
Y1 - 2020/4/2
N2 - Abatacept may exert its clinical effect on rheumatoid arthritis (RA) by suppressing anti-cyclic citrullinated peptide (CCP) antibody production. This study was undertaken to test this hypothesis by examining the changes of disease activity of RA and anti-CCP antibody levels over time after starting abatacept. Sixty Japanese RA patients who started abatacept were included in this multicenter, prospective observational study. Simple Disease Activity Index (SDAI) and anti-CCP antibody levels were evaluated at 12, 24, and 52 weeks. The mean SDAI score significantly decreased within 12 weeks after starting abatacept and was maintained thereafter. On the contrary, the mean anti-CCP antibody levels did not change until 52 weeks. At the individual level, there were substantial changes of anti-CCP antibody levels, but these were not correlated with the changes of disease activity at any time points. Thus, abatacept reduces the disease activity of RA independently of modulating anti-CCP antibody production.
AB - Abatacept may exert its clinical effect on rheumatoid arthritis (RA) by suppressing anti-cyclic citrullinated peptide (CCP) antibody production. This study was undertaken to test this hypothesis by examining the changes of disease activity of RA and anti-CCP antibody levels over time after starting abatacept. Sixty Japanese RA patients who started abatacept were included in this multicenter, prospective observational study. Simple Disease Activity Index (SDAI) and anti-CCP antibody levels were evaluated at 12, 24, and 52 weeks. The mean SDAI score significantly decreased within 12 weeks after starting abatacept and was maintained thereafter. On the contrary, the mean anti-CCP antibody levels did not change until 52 weeks. At the individual level, there were substantial changes of anti-CCP antibody levels, but these were not correlated with the changes of disease activity at any time points. Thus, abatacept reduces the disease activity of RA independently of modulating anti-CCP antibody production.
UR - http://www.scopus.com/inward/record.url?scp=85078469099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078469099&partnerID=8YFLogxK
U2 - 10.1080/25785826.2020.1718833
DO - 10.1080/25785826.2020.1718833
M3 - Article
C2 - 31994996
AN - SCOPUS:85078469099
VL - 43
SP - 87
EP - 91
JO - Immunological Medicine
JF - Immunological Medicine
SN - 0911-4300
IS - 2
ER -